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Abstract
Aims: To determine whether women with abnormal gestational diabetes (GDM) screening test 
results short of frank GDM have increased health-services utilization compared to women with 
normal results.
Methods: We conducted a retrospective-cohort study among 29,999 women enrolled in Kaiser 
Permanente Northwest who completed GDM screening (two-step method: 1-h, 50-g glucose-
challenge test (GCT); 3-h, 100-g oral-glucose-tolerance test (OGTT)). Test results were 
categorized as normal GCT (referent, n = 25,535), normal OGTT (n = 2246), abnormal OGTT but 
not GDM (n = 1477), and GDM (n = 741). Rate ratios (RRs) were calculated for utilization 
measures and analyses were age- and BMI-adjusted.
Results: Compared to women with normal GCT, rates for obstetrical ultrasound, noninvasive and 
invasive antenatal testing, and ambulatory visits to the obstetrics department were significantly 
greater among women with abnormal OGTT (RRs 1.2 [95%CI 1.1, 1.4], 1.3 [1.1, 1.4], 1.7 [1.3, 
2.3], and 1.1 [1.1, 1.1], respectively) and GDM (RRs 1.8, 1.8, 2.0, and 1.3, respectively). Women 
with abnormal OGTT results were more likely to visit a dietician than women with normal GCT; 
RRs ranged from 4.0 [3.3, 4.9] for women with abnormal GCT but normal OGTT to 72.1 [64, 81] 
for women with GDM.
Conclusions: Health-services utilization increased with severity of glucose result, even among 
women without GDM.
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1. Introduction
Gestational diabetes mellitus is one of the most frequently diagnosed complications of 
pregnancy. The prevalence of the condition is extremely sensitive to the diagnostic criteria 
used (Table 1), ranging from 1.1 to 25.5% depending on the diagnostic criteria and 
population screened [1]. Changing from the National Diabetes Data Group (NDDG) 
diagnostic criteria to the lower cut-points employed by Carpenter and Coustan criteria can 
increase the percentage of affected pregnancies by as much as 50% [2-5]. In 2009, new 
International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria with 
even lower cut-points and reliance upon one, rather than two, abnormal values were adopted 
by the American Diabetes Association. Under the new criteria, GDM diagnoses could 
increase two- to threefold, to a prevalence of approximately 15–20% [6]. Treatment of GDM 
includes a number of components, including referral for medical nutrition therapy, maternal 
blood glucose monitoring, and often more frequent obstetrical visits and ultrasounds.
A 2013 Consensus Development Conference by the National Institute of Health (NIH) 
convened to address controversial questions surrounding GDM screening concluded that 
there was not enough evidence to recommend universal adoption of a one-step approach to 
GDM screening [6]. Further, the panel recommended future research was needed to more 
fully understand resource implications of changing the thresholds for GDM diagnosis and to 
determine the “real world” impact of GDM treatment on health care utilization and practice 
patterns. Although health service utilization is expected to increase with increasing severity 
of glucose status, there currently is little documentation describing how much health service 
utilization differs among women with a GDM diagnosis and those with lower levels of GDM 
screening glucose test results that did not meet the threshold for diagnosing GDM. To better 
understand the potential health care utilization impact of switching to a GDM diagnostic test 
that would identify more women as having GDM, we sought to evaluate ambulatory health 
care utilization among women with different levels of glucose on screening and diagnostic 
test results who were receiving care in an integrated delivery system. Our hypothesis was 
that there would be an incremental increase in ambulatory health service utilization with 
increasing glucose levels.
2. Materials & methods
We conducted a retrospective cohort study using data from electronic medical records from 
Kaiser Permanente Northwest (KPNW), a large nonprofit prepaid, federally certified, Joint 
Commission-accredited, integrated delivery system with approximately 505,000 members in 
western Oregon and Washington State. Members include individuals and families covered 
by commercial group and individual self-pay health plans, Washington State Basic Health 
Plan (subsidized, Washington State only), Medicare Advantage, and Medicaid (Oregon and 
Washington State). Data used for analyses were extracted from the KPNW electronic 
medical record system and birth certificates. The linkage of medical records to birth 
certificates has been described elsewhere [7]. This study was approved by the Centers for 
Disease Control and Prevention (Protocol #3661, “Extent of Maternal Morbidity in a 
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Managed Care Setting”) and the KPNW Institutional Review Boards (Protocol: 
NW-02MHorn-02, approved 7/08/2002).
Our study population was comprised of women aged 18–55 years enrolled in KPNW at 
delivery with singleton births that occurred between January 1, 1999 and December 31, 
2008. To be included in the cohort, the pregnancy had to have reached at least 28.0 weeks 
gestation and GDM screening must have been completed between 24 weeks 0 days and 34 
weeks 6 days gestation. Pregnancies were not eligible for inclusion if the patient had an 
ICD-9 code for diabetes mellitus (DM) type 1 or 2 or listing on the KPNW diabetes registry 
as type 1 or 2 DM during or prior to pregnancy episode; a multifetal gestation; evidence of 
dispensing for insulin, metformin, or sulfonylurea prior to the date of the GDM screening 
test result; or a one hour test result of 140–199mg/dL with no 3 h test completed by 34 
weeks 6 days gestation.
We excluded pregnancies that were missing a documented delivery date, which was required 
for some outcome measures. We also excluded pregnancies missing data for covariates, 
including body mass index (BMI), parity, tobacco use, education, and Medicaid enrollment 
(Fig. 1). Medicaid enrollment, a proxy indicator of low socioeconomic status, is missing in 
records missing health plan enrollment data. Pregravid BMI (kg/m2) was calculated from 
adult height and weight (measured 180 days before to 91 days after pregnancy onset) 
documented in the electronic medical record. Covariate information was obtained from the 
medical record (age, BMI, Medicaid status) and from birth certificate (race/ethnicity, 
education, parity, tobacco use).
Within KNPW, universal GDM screening is performed at 24–28 weeks gestation for women 
without diabetes and also in early pregnancy for women at high risk for diabetes (e.g. 
women with obesity and/or prior history of GDM) [8-11]. Our prior studies have shown that 
completion of GDM screening occurs in over 95% of eligible women [9]. KPNW uses the 2-
step GDM screening method which involves a 1-h, 50-g oral glucose challenge test (GCT) 
followed by a 3-h, 100-g oral glucose tolerance test (OGTT) if the 1-h test is abnormal 
(>140 mg/dL). During the study period, GDM was diagnosed based on the NDDG criteria 
(Appendix A). Clinicians may have clinically managed women with a single abnormal value 
by NDDG criteria as GDM, but would not have diagnosed women as GDM by the lower 
Carpentar & Coustan cutpoints.
We categorized pregnancies based on glucose test results from the 1-hour GCT or 3-hour 
OGTT, by increasing severity of glycemia. Table 1 lists the criteria used to define the 5 
exposure categories which consisted of a normal GCT category, 3 categories of abnormal 
OGTT, and a GDM category. The outcomes of interest were 9 types of service utilization 
occurring >22 weeks gestation, as follows:
1. Any dispensing of capillary blood glucose test supplies (glucometer, test strips, 
lancets, control solution)
2. Any dispensing of a medication used to treat GDM (insulin, glyburide, 
metformin)
3. Number of obstetric ultrasounds
Vesco et al. Page 3
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Number of noninvasive antenatal tests [non-stress tests (NST), contraction stress 
tests (CST), and biophysical profiles performed by nurses at the time of a NST
5. Number of invasive antenatal tests (amniocentesis, cordocentesis)
6. Number of lab visits (counted as days, excluding the day of the initial GCT)
7. Number of ambulatory visits (counted as days) with:
a. obstetrics department (obstetrics and gynecology, perinatology, 
genetics)
b. nutrition department
c. urgent care, emergency department, or other departments (e.g. primary 
care, ophthalmology, etc)
8. Number of telephone encounters with any department listed above (counted as 
days)
9. Maternal length of stay (counted as days) for the delivery admission stratified by 
delivery type (cesarean or vaginal)
We assessed utilization of the above outcomes from 22 weeks gestation through delivery as 
this ensured lab tests related to GDM testing were included but avoided counting routine 
first prenatal visit lab tests, routine dating and anatomy ultrasounds, and other noninvasive 
and invasive screening tests that would typically occur early in pregnancy for reasons 
unrelated to glucose status. Other than maternal length of stay, we did not assess neonatal 
length of stay or any health outcomes for the mother or her infant. We stratified length of 
stay by cesarean and vaginal delivery due to the influence of mode of delivery on this 
measure [10]. We considered including antepartum lengths of stay that did not result in 
delivery, but exploration of these data showed many overlapping admissions and inter-
hospital transfers that precluded accurate electronic identification of this outcome.
We compared the glucose test result category and demographic characteristics of mothers 
included in the analysis with those who were excluded using chi square statistics for 
proportions. We then determined whether there was a difference in service utilization by 
glucose test result category and assigned women with a normal 1-hour GCT as the referent 
group. We analyzed the number of ultrasounds, noninvasive and invasive tests, lab visits, 
ambulatory visits and telephone encounters as rates (number of encounters/total person-
weeks from 22.0 weeks’ gestation to delivery because gestational age at delivery can vary). 
For these outcomes, we estimated rate ratios (RR) using generalized linear Poisson 
regression models, with a negative binomial distribution and person-weeks from 22 weeks 
gestation to delivery as the offset variable. Logistic regression models were used for 
dichotomous outcomes (dispensing of glucose testing supplies or GDM medications). Linear 
regression was used to assess differences in delivery length of stay by delivery type 
(cesarean versus vaginal). All models accounted for repeated measures (women with more 
than 1 pregnancy in the study) using generalized estimating equations. The logistic models 
were adjusted for age and BMI only as the addition of multiple covariates caused model 
instability due to small cell sizes, and the linear and Poisson models were adjusted for 
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covariates (age, BMI, race/ethnicity, education, parity, tobacco use, and Medicaid status). As 
a sensitivity analysis to determine whether another common antepartum condition aside 
from abnormal glucose levels may be influencing the results, we reran the logistic and linear 
regression models after excluding women with hypertensive disorders. Tests for linear trends 
across glucose test result categories were performed using linear contrasts. Statistical 
significance was set at p < 0.05. Statistical analyses were run in Statistical Analysis Software 
(SAS) version 9.3 (SAS Institute, Cary, NC).
3. Results
Our study sample included 29,999 pregnancies to 24,615 women; 2.5% of pregnancies met 
the NDDG diagnostic criteria for GDM used during the study period. Compared to 
pregnancies included in the analyses, those that were excluded were among women who 
were younger, more likely to use tobacco and to be insured by Medicaid, and less likely to 
be married or to have more than a high school education (data not shown, p < .0001). There 
were also some differences in race/ethnicity, such that the excluded pregnancies had a higher 
proportion of racial ethnic minorities (Black, Hispanic, and Asian/Pacific Islander) and 
Other/Multiple/Unknown race categories (p < .0001). The pregnancies excluded from the 
analysis were also less likely to have abnormal glucose test results and less likely to meet 
threshold for GDM diagnosis (p= .0012).
Among pregnancies included in the analyses, severity of the glucose test result increased 
with age and BMI. The proportion of women with abnormal glucose test results was lower 
among those insured by Medicaid and higher among those with less than a high school 
education (Table 2). Diagnosis of GDM was highest among women of Asian/Pacific Islander 
and Hispanic backgrounds (6.1 and 3.3%, respectively), compared to those of non-Hispanic 
Black (2.0%) and non-Hispanic White (1.9%) backgrounds.
As expected, over 90% of pregnancies with GDM had a dispensing for GDM testing 
supplies (Table 3). Among women with one abnormality by NDDG criteria, 16.6% were 
treated as if they had GDM (i.e, dispensed glucose testing supplies). The majority of women 
with 1–2 abnormalities by Carpenter & Coustan criteria were not treated as if they had GDM 
(only 3% dispensed glucose testing supplies. The proportion of pregnancies with medication 
dispensing to treat GDM was 8.5% among pregnancies with GDM and 3.7% among women 
with 1 abnormal value by NDDG criteria. Only 5 women, among the nearly 28,500 women 
with lesser to no glucose abnormalities were dispensed a medication used to treat GDM.
The rate of obstetric ultrasounds and noninvasive and invasive antenatal tests after 22 weeks’ 
gestation increased with severity of glucose test result such that the rate ratios for 
pregnancies with GDM were nearly twice as high compared to pregnancies with a normal 
GCT. There was little variation in laboratory visits by severity of glucose test result other 
than the additional OGTT test required of those who failed the GCT.
The increase in the rate of ambulatory visits by severity of glucose test result was most 
notable for Ob/Gyn and nutrition visits (Table 3). Compared to pregnancies with a normal 
GCT, the rate ratio (RR) for Ob/Gyn visits was 1.1 (95% CI 1.1, 1.1) and 1.3 (95% CI 
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1.3,1.4) among pregnancies with 1 abnormality by NDDG or GDM, respectively. For 
nutrition visits, the RR was higher for pregnancies with any glucose abnormality ranging 
from 4.0 (95% CI 3.3, 4.9) among pregnancies with an abnormal GCT but normal OGTT to 
72 (95% CI 64, 81) among pregnancies with GDM. Women with GDM had a 3-fold greater 
rate of phone encounters than women with normal testing.
Cesarean delivery occurred in 25.0% of pregnancies but was most common among women 
with 1–2 abnormal values by the Carpenter & Coustan criteria (36.1%). Cesarean delivery 
occurred in 24.0% of deliveries among women with normal testing, 34.0% of deliveries 
among women with one abnormal value by NDDG criteria, and 32% of deliveries among 
women with GDM (chi square p < .0001; data not shown). Maternal lengths of stay for 
vaginal and cesarean delivery did not differ substantially by glucose category.
The results of our analyses did not change when women with hypertensive disorders (n = 
2,290; 7.6%) were excluded (Supplemental Table).
4. Discussion
The results of our study show that, compared to women with normal GDM test results, there 
was a greater use of several health care services among women with GDM as well as among 
women with glucose test results that were abnormal but did not meet the threshold for GDM 
diagnosis. About 10% of women with glucose test results below the diagnostic thresholds of 
GDM were dispensed supplies related to glucose testing and management. We suspect they 
were treated as having GDM based on either maternal or clinical risk factors that are 
associated with GDM, such as obesity, polyhydramnios or large-for-gestational age fetus, or 
based on the presence of GDM risk factors in combination with an abnormal but 
nondiagnostic test result. However, the number of women with subdiagnostic test results 
treated as GDM (just over 150 women) is small compared to the additional number of 
women that would be diagnosed and treated with GDM if our health care system switched to 
lower diagnostic thresholds. In our population, we approximate that as many as 1500 more 
women would have met criteria for GDM during our study period if lower diagnostic 
thresholds were utilized (such as those based on IADPSG and/or C&C criteria), which 
would be a 3-fold increase in prevalence from 2.5% to 7.4% of those screened.
For the health care system, the increased staffing needs for management of GDM if 
conversion to lower diagnostic thresholds was implemented could be substantial, especially 
for those staff that are required to provide dietary consultation and feedback (e.g. telephone 
calls), capillary blood glucose surveillance, and antenatal testing. To demonstrate the 
potential impact of diagnosing more women with GDM, we estimated service utilization for 
GDM diet teaching, blood sugar management, and antenatal surveillance; and how it could 
be impacted by a tripling of the volume of women with GDM (Table 4). For the estimates, 
we assumed all women with GDM have weekly blood sugar reviews for an average of 13 
weeks (26–39 weeks); see a dietitian for a single, one-hour teaching visit; and start antenatal 
testing twice weekly at 32 weeks if they are on medication. Given these estimates, the 
number of case management contacts per year could increase from 6500 for 500 women 
with GDM to 19,500 for 1500 women with GDM, dietitian visits could increase from 500 h 
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to 1500 h per year, and antenatal testing visits could range from 280 to 840 per year. The 
ACOG practice bulletin for GDM indicates there is some leeway for local practices to 
determine the frequency of antenatal and capillary blood sugar surveillance as well as the 
timing of delivery [11], so the full impact of GDM diagnosis on staffing could be variable 
depending on local practices for these services. In our practice model, for a single woman 
diagnosed with GDM at 26 weeks who requires medication prior to, or by 32 weeks, and 
delivers at 39 weeks, the minimum amount of additional time above and beyond routine 
prenatal care that is required by the case management telephone calls, antenatal surveillance 
(twice weekly NST and AFI), and dietitian visit is 11.5 contact hours. This does not include 
the time the patient spends traveling to and from the office to attend her prenatal and 
antenatal testing visits, or the time she spends testing her blood sugars.
While it was tempting to attach a cost analysis with these data, we intentionally did not do 
so because other health care systems may differ from ours in their cost structures. Further, 
another important aspect of a cost analysis is consideration of cost to the patient. The cost of 
GDM diagnosis to the patient is not only financial due to copays, cost of supplies and 
medications, and lost time at work, but also includes the social-emotional impact of the 
diagnosis. In a past study examining medical costs associated with gestational diabetes, 
researchers generated estimates of an excess cost due to GDM of $3305 per pregnancy, plus 
an excess cost of $209 in the first year of life for each newborn. Total estimated medical 
costs attributable to GDM were $636 million for 2007, $230 million of which was covered 
by government programs [12]. If the prevalence of GDM abruptly increases by wide spread 
adoption of lower diagnostic thresholds, health system and patient costs related to diagnosis 
and treatment of GDM could substantially increase. Whether this increased expenditure for 
GDM-related care would be balanced out by reduction in adverse pregnancy outcomes and 
long-term maternal and child health requires further study. Preliminary studies in U.S. and 
Canadian populations have not shown improved outcomes among women with GDM 
diagnosed at lower thresholds [13,14], A recent study comparing the use of Carpentar & 
Coustan with the IADPSG criteria for GDM diagnosis found an increase in the rate of 
cesarean delivery for women diagnosed by the IADPSG criteria, without a reduction in the 
rate of LGA, macrosomia, NICU admissions, preterm birth, preeclampsia, shoulder 
dystocia, or hyperbilirubinemia [14].
Strengths of our analyses include that we had access to multiple years of data within a large 
health care system with universal screening and standardized protocols of care and 
diagnostic cut points, which limits bias due to failure to screen and limits variability in 
provider practice allowing for better observation of utilization by GDM test result. Although 
our data come from an insured population, this may be the most useful scenario to estimate 
the upper limits of health care service burden related to GDM; whereas, data from uninsured 
or underinsured population may underestimate this burden. Most women included in our 
study cohort would have had access to recommended supplies, medications, and services. 
The GDM prevalence in this study cohort (2.5%) is lower than would be expected if women 
screened for GDM at all gestational ages were included. Women diagnosed with GDM early 
in pregnancy may better represent those with pregestational glucose abnormalities and, as 
such, would potentially have an even greater utilization of health care services than those 
diagnosed at the time of routine screening (24–28 weeks gestation). Limitations of our 
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analyses include our inability to directly evaluate the utilization of care among women 
diagnosed with GDM by diagnostic criteria with thresholds lower than those of the NDDG 
cut-points utilized in this study. While we examined categories of glucose abnormalities that 
would approximate the milder abnormalities detected with the lower C&C and IADPSG 
thresholds, these abnormalities were not clinically recognized in our population and, thus, 
the impact on health care utilization of a GDM diagnosis at these lower thresholds could not 
be ascertained. One potential bias to this analysis is that we excluded pregnancies for which 
data regarding our prespecified covariates were not available. In our analysis of included 
versus excluded pregnancies, we found the excluded population to be younger with less 
likelihood for abnormal glucose test results. Unless the excluded women were high utilizers 
of health care, it is unlikely that the dose response relationship observed in the study would 
have been impacted by the exclusion of these women. Our sensitivity analysis, which 
additionally excluded women with hypertensive disorders during pregnancy, provides 
additional strength for the observed relationship. The characteristics of our study population 
limit the generalizability of our results; however, it seems likely that patient populations 
from other backgrounds or health care systems would also have increased levels of 
utilization with a GDM diagnosis given recommendations from ACOG and the ADA for 
management of women with diabetes in pregnancy [11,15].
In summary, health care utilization increased with severity of glucose test result, even among 
women not meeting criteria for GDM by NDDG criteria. Further study is needed to 
determine whether lowering diagnostic thresholds, resulting in a substantially larger 
proportion of women with GDM, improves maternal and child health outcomes and whether 
the additional patient and health care system related costs of increased detection are offset 
by a reduction in adverse outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix A
Criteria for abnormal result on an oral glucose tolerance test (OGTT) for the diagnosis of 
gestational diabetes mellitus (GDM)
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Appendix B. Supplementary material
Supplementary data to this article can be found online at https://doi.org/10.1016/j.diabres.
2019.04.025.
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Fig. 1 - 
Description of study sample selection.
Vesco et al. Page 11
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vesco et al. Page 12
Ta
bl
e 
1 
-
Cr
ite
ria
 u
se
d 
to
 c
at
eg
or
iz
e 
w
o
m
en
 b
as
ed
 o
n 
gl
uc
os
e 
te
st 
re
su
lt.
W
o
m
en
 c
a
te
go
ri
ze
d 
as
:
C
ri
te
ri
a 
us
ed
:
N
or
m
al
 G
CT
1-
h,
 5
0 
g 
G
CT
: 
<
14
0 
m
g/
dL
N
or
m
al
 O
G
TT
 b
y 
N
D
D
G
 a
nd
 C
C
3-
h,
 1
00
 g
 O
G
TT
 (a
ll c
rit
eri
a m
et)
:
fa
st
in
g 
<9
5 
m
g/
dL
, 1
-h
 <
 1
80
 m
g/
dL
, 2
-h
 <
 1
55
 m
g/
dL
, 3
 h
 <
14
0 
m
g/
dL
1–
2 
A
bn
or
m
al
 b
y 
CC
, b
u
t n
ot
 b
y 
N
D
D
G
3-
h,
 1
00
 g
 O
G
TT
 (1
–2
 cr
ite
ria
 m
et)
:
fa
st
in
g 
95
–1
05
 m
g/
dL
, 1
-h
 1
80
–1
90
 m
g/
dL
, 2
-h
 1
55
–1
65
 m
g/
dL
, 3
 h
 1
40
–1
45
 m
g/
dL
1 
A
bn
or
m
al
 b
y 
N
D
D
G
3-
h,
 1
00
 g
 O
G
TT
 (o
nly
 1 
cri
ter
ia 
me
t):
fa
st
in
g 
>1
05
 m
g/
dL
, 1
-h
 >
 1
90
 m
g/
dL
, 2
-h
 >
 1
65
 m
g/
dL
, 3
 h
 >
 1
45
 m
g/
dL
G
D
M
1-
h,
 5
0 
g 
G
CT
: 
>
20
0 
m
g/
dL
O
R
3-
h,
 1
00
 g
 O
G
TT
 (≥
2 c
rit
eri
a m
et)
:
fa
st
in
g 
> 
10
5 
m
g/
dL
, 1
-h
 >
 1
90
 m
g/
dL
, 2
-h
 >
 1
65
 m
g/
dL
, 3
 h
 >
 1
45
 m
g/
dL
A
bb
re
v
ia
tio
ns
: 
G
CT
,
 
gl
uc
os
e 
ch
al
le
ng
e 
te
st;
 O
G
TT
,
 
o
ra
l g
lu
co
se
 to
le
ra
nc
e 
te
st;
 G
D
M
, g
es
ta
tio
na
l d
ia
be
te
s m
el
lit
us
.
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vesco et al. Page 13
Ta
bl
e 
2 
-
M
at
er
na
l c
ha
ra
ct
er
ist
ic
s b
y 
gl
uc
os
e 
te
st 
re
su
lt.
C
ha
ra
ct
er
ist
ic
N
or
m
al
 G
C
T
(n
 = 
25
,53
5, 
85
.1%
)
N
or
m
al
 O
G
TT
 b
y 
C
C
 &
N
D
D
G
 (n
 = 
22
46
, 7
.5%
)
1–
2 
A
bn
or
m
al
C
C
 (n
 = 
65
7, 
2.2
%
)
1 
A
bn
or
m
al
 b
y
N
D
D
G
(n
 = 
82
0, 
2.7
%
)
G
D
M
(n
 = 
74
1, 
2.5
%
)
%
%
%
%
%
A
ge
 (y
ea
rs)
a
 
<
25
90
.8
5.
6
1.
2
1.
2
1.
2
 
25
–2
9
85
.6
7.
3
2.
2
2.
6
2.
3
 
30
–3
4
82
.2
8.
4
2.
6
3.
6
3.
2
 
≥3
5
77
.9
10
.1
3.
4
4.
4
4.
2
R
ac
e/
Et
hn
ic
ity
a
 
N
H
-W
hi
te
86
.9
7.
0
1.
9
2.
3
1.
9
 
N
H
-B
la
ck
90
.4
4.
4
1.
7
1.
4
2.
0
 
H
isp
an
ic
81
.5
8.
9
2.
7
3.
6
3.
3
 
A
sia
n/
Pa
ci
fic
 Is
la
nd
er
70
.0
13
.9
4.
3
5.
8
6.
1
 
M
ul
tip
le
/O
th
er
/U
nk
no
w
n
75
.8
9.
5
3.
8
5.
1
5.
8
Ed
uc
at
io
n 
(ye
ars
)a
 
<
12
83
.3
7.
3
2.
3
3.
1
4.
0
 
12
85
.8
7.
2
2.
2
2.
7
2.
1
 
>
12
85
.1
7.
6
2.
2
2.
7
2.
5
M
ed
ic
ai
da
 
Ye
s
89
.2
5.
6
1.
5
1.
9
1.
9
 
N
o
84
.9
7.
6
2.
2
2.
8
2.
5
Pa
rit
y
 
0
85
.4
7.
3
2.
1
2.
6
2.
6
 
≥1
84
.9
7.
7
2.
2
2.
8
2.
4
Sm
ok
er
 
Ye
s
85
.5
7.
2
2.
6
2.
2
2.
5
 
N
o
85
.1
7.
5
2.
1
2.
8
2.
5
B
M
I (
kg
/m
2 )a
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vesco et al. Page 14
C
ha
ra
ct
er
ist
ic
N
or
m
al
 G
C
T
(n
 = 
25
,53
5, 
85
.1%
)
N
or
m
al
 O
G
TT
 b
y 
C
C
 &
N
D
D
G
 (n
 = 
22
46
, 7
.5%
)
1–
2 
A
bn
or
m
al
C
C
 (n
 = 
65
7, 
2.2
%
)
1 
A
bn
or
m
al
 b
y
N
D
D
G
(n
 = 
82
0, 
2.7
%
)
G
D
M
(n
 = 
74
1, 
2.5
%
)
%
%
%
%
%
 
<
25
88
.0
6.
8
1.
4
1.
9
1.
9
 
25
.0
–2
9.
9
84
.4
7.
7
2.
2
2.
9
2.
8
 
21
 ≥
 3
0.
0
79
.1
8.
8
4.
0
4.
6
3.
6
a C
hi
-s
qu
ar
e 
<0
.0
5.
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vesco et al. Page 15
Ta
bl
e 
3 
-
D
ist
rib
u
tio
n 
an
d 
re
gr
es
sio
n 
re
su
lts
 fo
r s
er
vi
ce
 u
til
iz
at
io
n 
m
ea
su
re
s b
y 
se
v
er
ity
 o
f g
lu
co
se
 te
st 
re
su
lt.
Se
rv
ic
e 
ut
ili
za
tio
n 
m
ea
su
re
G
D
M
 sc
re
en
in
g 
te
st
 re
su
lt
N
or
m
al
 G
C
T
(n
 = 
25
,53
5, 
85
.1%
)
N
or
m
al
 O
G
TT
 b
y
C
C
 &
 N
D
D
G
(n
 = 
2,2
46
, 7
.5%
)
1–
2 
A
bn
or
m
al
by
 C
C
 (n
 = 
65
7, 
2.2
%
)
1 
A
bn
or
m
al
 b
y
N
D
D
G
 (n
 = 
82
0, 
2.7
%
)
G
D
M
 (n
 = 
74
1, 
2.5
%
)
D
isp
en
se
d 
gl
uc
os
e 
te
sti
ng
 su
pp
lie
sa
 
%
 y
es
0.
2
1.
9
3.
0
16
.6
93
.2
 
O
R 
(95
%C
I)d
1.
0
6.
9
10
.0
65
.0
51
51
re
fe
re
nt
(4.
6, 
10
.3)
(5.
9, 
16
.9)
(47
.1,
 89
.7)
(35
16
, 7
54
5)
D
isp
en
se
d 
m
ed
ic
at
io
ns
 fo
r G
D
M
a
 
%
 y
es
0
0.
1
0.
1
3.
7
8.
5
 
O
R 
(95
%C
I)
M
od
el
 n
ot
 a
bl
e 
to
 ru
n 
to
 d
ue
 sm
al
l c
el
l s
iz
es
O
bs
te
tri
ca
l u
ltr
as
ou
nd
b
 
N
um
be
r o
f e
nc
ou
nt
er
s
1.
2
1.
3
1.
4
1.
6
2.
3
 
R
R
 (9
5%
 C
I)d
1.
0
1.
0
1.
1
1.
2
1.
8
re
fe
re
nt
(1.
0, 
1.1
)
(0.
9, 
1.2
)
(1.
1, 
1.4
)
(1.
6, 
2.0
)
N
on
in
v
as
iv
e 
an
te
na
ta
l t
es
tsb
 
N
um
be
r o
f e
nc
ou
nt
er
s
1.
7
1.
9
2.
0
2.
4
3.
3
 
R
R
 (9
5%
 C
I)d
1.
0
1.
1
1.
1
1.
3
1.
8
re
fe
re
nt
(1.
0, 
1.2
)
(1.
0, 
1.2
)
(1.
1, 
1.4
)
(1.
7, 
2.0
)
In
v
as
iv
e 
an
te
na
ta
l t
es
tsb
 
N
um
be
r o
f e
nc
ou
nt
er
s
0.
05
0.
07
0.
06
0.
10
0.
11
 
R
R
 (9
5%
 C
I)d
1.
0
1.
2
0.
9
1.
7
2.
0
re
fe
re
nt
(1.
0, 
1.6
)
(0.
6, 
1.5
)
(1.
3, 
2.3
)
(1.
5, 
2.7
)
La
bo
ra
to
ry
 v
isi
tsb
 
N
um
be
r o
f e
nc
ou
nt
er
s
1.
6
2.
8
2.
8
2.
9
2.
8
 
R
R
 (9
5%
 C
I)d
1.
0
1.
7
1.
7
1.
8
1.
7
re
fe
re
nt
(1.
7, 
1.8
)
(1.
6, 
1.8
)
(1.
7, 
1.9
)
(1.
7, 
1.8
)
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vesco et al. Page 16
Se
rv
ic
e 
ut
ili
za
tio
n 
m
ea
su
re
G
D
M
 sc
re
en
in
g 
te
st
 re
su
lt
N
or
m
al
 G
C
T
(n
 = 
25
,53
5, 
85
.1%
)
N
or
m
al
 O
G
TT
 b
y
C
C
 &
 N
D
D
G
(n
 = 
2,2
46
, 7
.5%
)
1–
2 
A
bn
or
m
al
by
 C
C
 (n
 = 
65
7, 
2.2
%
)
1 
A
bn
or
m
al
 b
y
N
D
D
G
 (n
 = 
82
0, 
2.7
%
)
G
D
M
 (n
 = 
74
1, 
2.5
%
)
A
m
bu
la
to
ry
 v
isi
tsb
 
O
B/
G
yn
 
 
N
um
be
r o
f e
nc
ou
nt
er
s
8.
1
8.
1
8.
4
8.
9
10
.8
 
 
R
R
 (9
5%
 C
I)d
1.
0
1.
0
1.
0
1.
1
1.
3
re
fe
re
nt
(1.
0, 
1.0
)
(1.
0, 
1.1
)
(1.
1, 
1.1
)
(1.
3, 
1.4
)
N
ut
rit
io
n
 
 
N
um
be
r o
f e
nc
ou
nt
er
s
0.
0
0.
1
0.
1
0.
5
1.
1
 
 
R
R
 (9
5%
 C
I)d
1.
0
4.
0
5.
3
30
.1
72
.1
re
fe
re
nt
(3.
3, 
4.9
)
(4.
0, 
7.1
)
(26
.1,
 34
.7)
(64
.0,
 81
.3)
 
U
rg
en
t/E
m
er
ge
nt
/O
th
er
 
 
N
um
be
r o
f e
nc
ou
nt
er
s
3.
2
3.
3
3.
2
3.
4
3.
2
 
 
R
R
 (9
5%
 C
I)d
1.
0
1.
1
1.
0
1.
1
1.
1
re
fe
re
nt
(1.
0, 
1.1
)
(1.
0, 
1.1
)
(1.
0, 
1.2
)
(1.
0, 
1.2
)
Te
le
ph
on
e 
en
co
un
te
rs
 
N
um
be
r o
f e
nc
ou
nt
er
s
2.
8
4.
1
4.
3
5.
2
8.
2
 
R
R
 (9
5%
 C
I)d
1.
0
1.
5
1.
5
1.
9
3.
1
re
fe
re
nt
(1.
4, 
1.5
)
(1.
5, 
1.6
)
(1.
8, 
2.0
)
(2.
9, 
3.2
)
M
at
er
na
l d
el
iv
er
y 
le
ng
th
 o
f s
ta
yc
 
O
ve
ra
ll 
(da
ys
)
3.
5
3.
6
3.
8
3.
8
3.
8
 
 
β (
95
% 
CI
)d
0.
0
0.
0
0.
2
0.
1
0.
2
R
ef
er
en
t
(0.
0, 
0.1
)
(0.
1, 
0.3
)
(0.
1, 
0.2
)
(0.
1, 
0.2
)
 
Ce
sa
re
an
 b
irt
hs
 (d
ay
s)
4.
6
4.
6
4.
8
4.
8
4.
7
 
 
β (
95
% 
CI
)
0.
0
−
0.
0
0.
1
0.
1
0.
0
R
ef
er
en
t
(−
0.1
, 0
.1)
(−
0.0
, 0
.3)
(−
0.0
, 0
.2)
(−
0.1
, 0
.2)
 
Va
gi
na
l (
da
ys
)
3.
2
3.
3
3.
3
3.
3
3.
4
 
 
β (
95
% 
CI
)d
0.
0
0.
1
0.
1
0.
1
0.
2
R
ef
er
en
t
(0.
0, 
0.1
)
(−
0.0
, 0
.2)
(0.
0, 
0.2
)
(0.
1, 
0.3
)
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vesco et al. Page 17
A
bb
re
v
ia
tio
ns
: 
G
CT
,
 
gl
uc
os
e 
ch
al
le
ng
e 
te
st;
 O
G
TT
,
 
o
ra
l g
lu
co
se
 to
le
ra
nc
e 
te
st;
 C
C,
 C
ar
pe
nt
er
 a
nd
 C
ou
sta
n;
 N
D
D
G
, N
at
io
na
l D
ia
be
te
s D
at
a 
G
ro
up
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; O
R,
 o
dd
s r
at
io
; R
R,
 ra
te
 ra
tio
.
a D
ic
ho
to
m
ou
s o
ut
co
m
es
 (y
es/
no
) a
na
lyz
ed
 w
ith
 lo
gis
tic
 re
gr
es
sio
n 
m
od
el
s t
o 
es
tim
at
e 
od
ds
 ra
tio
s (
OR
) a
cc
ou
nti
ng
 fo
r r
ep
ea
ted
 m
ea
su
res
 (w
o
m
en
 w
ith
 m
or
e 
th
an
 1
 p
re
gn
an
cy
 in
 th
e 
stu
dy
) a
nd
 ad
jus
tin
g f
or 
ag
e 
an
d 
BM
I. 
Th
e 
ad
di
tio
n 
of
 m
ul
tip
le
 c
ov
ar
ia
te
s c
au
se
d 
m
od
el
 in
sta
bi
lit
y 
du
e 
to
 sm
al
l c
el
l s
iz
es
 a
nd
 th
er
ef
or
e 
th
e 
lo
gi
sti
c 
re
gr
es
sio
n 
an
al
ys
es
 w
er
e 
ad
jus
ted
 on
ly 
for
 ag
e a
nd
 B
MI
.
b R
at
e 
ou
tc
om
es
 c
al
cu
la
te
d 
as
 n
um
be
r o
f e
nc
ou
nt
er
s d
iv
id
ed
 b
y 
to
ta
l p
er
so
n-
w
ee
ks
 fr
om
 >
22
 w
ee
ks
 g
es
ta
tio
n 
to
 d
el
iv
er
y 
an
d 
an
al
yz
ed
 w
ith
 g
en
er
al
iz
ed
 li
ne
ar
 P
oi
ss
on
 re
gr
es
sio
n 
m
od
el
s, 
w
ith
 a
 n
eg
at
iv
e 
bi
no
m
ia
l d
ist
rib
u
tio
n 
an
d 
pe
rs
on
-w
ee
ks
 fr
om
 2
2 
w
ee
ks
 g
es
ta
tio
n 
to
 d
el
iv
er
y 
as
 th
e 
of
fs
et
 v
ar
ia
bl
e 
to
 e
sti
m
at
e 
ra
te
 ra
tio
s (
RR
). I
n s
itu
ati
on
s w
he
re 
the
re 
we
re 
no
 ze
ro 
co
un
ts,
 w
e m
od
ele
d t
he
 nu
mb
er 
of 
“
ex
ce
ss
” 
co
u
n
ts
. A
ll 
m
od
el
s a
cc
ou
nt
ed
 fo
r r
ep
ea
te
d 
m
ea
su
re
s (
wo
m
en
 w
ith
 m
or
e 
th
an
 1
 p
re
gn
an
cy
 in
 th
e 
stu
dy
) a
nd
 w
ere
 ad
jus
ted
 fo
r a
ge
, B
MI
, ra
ce/
eth
nic
ity
,
 
ed
uc
at
io
n,
 p
ar
ity
,
 
to
ba
cc
o 
us
e,
 a
nd
 M
ed
ic
ai
d 
st
at
us
.
c L
in
ea
r o
ut
co
m
es
 (d
ay
s) 
we
re 
an
aly
ze
d w
ith
 lin
ea
r g
en
era
liz
ed
 es
tim
ati
ng
 eq
ua
tio
n m
od
els
 to
 es
tim
ate
 a 
β c
o
ef
fic
ie
nt
. A
ll 
m
od
el
s a
cc
ou
nt
ed
 fo
r r
ep
ea
te
d 
m
ea
su
re
s (
wo
m
en
 w
ith
 m
or
e 
th
an
 1
 p
re
gn
an
cy
 in
 
th
e 
stu
dy
) a
nd
 w
ere
 ad
jus
ted
 fo
r a
ge
, B
MI
, ra
ce/
eth
nic
ity
,
 
ed
uc
at
io
n,
 p
ar
ity
,
 
to
ba
cc
o 
us
e,
 a
nd
 M
ed
ic
ai
d 
sta
tu
s.
d L
in
ea
r t
re
nd
 p
 <
 0
.0
5.
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vesco et al. Page 18
Ta
bl
e 
4 
-
O
ne
 y
ea
r s
er
vi
ce
 v
o
lu
m
e 
es
tim
at
es
 fo
r w
o
m
en
 w
ith
 a
 G
D
M
 d
ia
gn
os
is.
W
o
m
en
 w
ith
 G
D
M
C
as
e
m
a
n
a
ge
m
en
t c
al
ls
C
as
e m
an
ag
er
ho
ur
s
N
ut
ri
tio
n
v
isi
ts
D
ie
tit
ia
n
ho
ur
s
A
nt
en
at
al
te
st
s
A
nt
en
at
al
n
u
rs
e 
ho
ur
s
10
0
13
00
32
5
10
0
10
0
11
2
56
50
0
65
00
16
25
50
0
50
0
56
0
28
0
10
00
13
,0
00
32
50
10
00
10
00
11
20
56
0
15
00
19
,5
00
48
75
15
00
15
00
16
80
84
0
A
ss
um
pt
io
ns
: 
Av
er
ag
e 
13
 w
ee
ks
 in
 c
as
e 
m
an
ag
em
en
t (
26
–3
9 w
ee
ks
 ge
sta
tio
n) 
wi
th 
mi
nim
um
 of
 on
ce
 w
ee
kly
 bl
oo
d s
ug
ar
 r
ev
ie
w
 a
n
d 
15
 m
in
 ca
se
 m
an
ag
em
en
t c
al
ls;
 6
0 
m
in
 d
ie
tit
ia
n 
vi
sit
s; 
8%
 o
f G
D
M
 
pa
tie
nt
s r
eq
ui
re
 m
ed
ic
at
io
n 
an
d 
un
de
rg
o 
tw
ic
e 
w
ee
kl
y 
an
te
na
ta
l t
es
tin
g 
fo
r a
n 
av
er
ag
e 
of
 7
 w
ee
ks
 (3
2–
39
 w
ee
ks
) w
ith
 30
 m
in 
an
ten
ata
l te
sti
ng
 vi
sit
s.
Diabetes Res Clin Pract. Author manuscript; available in PMC 2020 June 01.
